Cost‐effectiveness of thiopurine methyltransferase genotype screening in IBD
Authors:
Open Access
- 17 March 2005
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 21 (6) , 790-791
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Cost‐effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2004
- Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.2002
- Monitoring for drug side‐effects in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2002
- Management of Crohn's disease in adultsAmerican Journal of Gastroenterology, 2001
- Frequency of Use and Standards of Care for the Use of Azathioprine and 6-Mercaptopurine in Treatment of Inflammatory Bowel Disease: A Systematic Review of the Literature and a Survey of Canadian GastroenterologistsCanadian Journal of Gastroenterology and Hepatology, 2001
- Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapyGastroenterology, 2000
- Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphismClinical Pharmacology & Therapeutics, 1989